These anorexigenic and weight‐suppressive actions make GDF15 a very attractive molecule from a translational point of view, encouraging potential applications in the treatment of obesity, metabolic disorders, but also feeding and eating disorders [13, 44]. The gene discussed is GDF15; the disease is Other metabolic disease.